Ovarian Carcinoma CRISPR Knockout Models for Drug Discovery

Ovarian carcinoma is the eighth most common cancer in women worldwide and the leading cause of gynecologic cancer death. According to the World Health Organization (WHO) GLOBOCAN 2020, there were approximately 313,959 new cases and 207,252 deaths globally. The 5-year survival rate for ovarian cancer varies significantly by stage at diagnosis: localized (Stage I) survival is about 93%, regional (Stage II-III) survival drops to 75%, and distant (Stage IV) survival is only 31% (National Cancer Institute SEER data, 2010-2019). Key risk factors include age, family history, BRCA1/BRCA2 mutations, endometriosis, and nulliparity. The high mortality is largely due to late-stage diagnosis and the development of chemoresistance.

Ovarian carcinoma is an ideal model for mechanistic studies due to its well-defined histological subtypes (high-grade serous, endometrioid, clear cell, mucinous) and distinct molecular profiles. High-grade serous ovarian carcinoma (HGSOC) is the most common and aggressive subtype, characterized by near-universal TP53 mutations and frequent homologous recombination deficiency (HRD). Public datasets from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) provide extensive genomic, transcriptomic, and proteomic data. Open research questions include the mechanisms of platinum and PARP inhibitor resistance, the role of the tumor microenvironment, and the identification of novel synthetic lethal targets.

• • Ovarian carcinogenesis involves several key pathways:
• • TP53 pathway: Loss of p53 function is a hallmark of HGSOC, leading to genomic instability and impaired apoptosis.
• • Homologous Recombination (HR) pathway: Mutations in BRCA1, BRCA2, and other HR genes (e.g., RAD51C, PALB2) cause defective DNA repair, promoting tumorigenesis and sensitivity to PARP inhibitors.
• • PI3K/AKT/mTOR pathway: Activating mutations in PIK3CA or loss of PTEN are common in endometrioid and clear cell subtypes, driving cell survival and proliferation.
• • WNT/beta-catenin pathway: CTNNB1 mutations are frequent in endometrioid ovarian carcinoma, leading to constitutive transcriptional activation of target genes.

Data from TCGA (2011) and COSMIC (v96).

• • Key signaling networks deregulated in ovarian carcinoma include:
• • PI3K/AKT/mTOR:
• • Upstream: PIK3CA activating mutations, PTEN loss.
• • Downstream: AKT phosphorylation, mTORC1 activation, increased protein synthesis and cell growth.
• • MAPK/ERK:
• • Upstream: KRAS or BRAF mutations (common in low-grade serous).
• • Downstream: MEK and ERK phosphorylation, promoting proliferation and survival.
• • DNA Damage Response (DDR):
• • HR deficiency (BRCA1/2 mutations) leads to reliance on alternative repair pathways (e.g., NHEJ, alt-EJ).
• • PARP1 is a key target for synthetic lethality in HR-deficient tumors.
• • Notch signaling:
• • Notch receptors and ligands (JAG1, DLL4) are overexpressed in HGSOC, promoting cancer stem cell maintenance and invasion.

Organoid models derived from patient tumors retain the genetic and histological features of the original tumor, including stromal interactions, and are valuable for drug sensitivity testing and personalized medicine approaches.

• • Patient-Derived Xenografts (PDX): Tumor fragments from patients are implanted into immunodeficient mice (e.g., NSG). PDX models preserve tumor heterogeneity and are used for preclinical drug testing.
• • Genetically Engineered Mouse Models (GEMM): Conditional knockout of Brca1, Trp53, and Pten in the ovarian surface epithelium (e.g., using AdCre) recapitulates HGSOC.
• • Induced Models: Injection of syngeneic cell lines (e.g., ID8) into immunocompetent mice to study immune interactions and test immunotherapies.

• • CRISPR/Cas9 technology enables the generation of isogenic cell lines with precise genetic modifications. For ovarian carcinoma research, common models include:
• • TP53 knockout lines: In TP53 wild-type cells (e.g., SKOV3, A2780), knockout of TP53 recapitulates the loss of p53 function seen in HGSOC, allowing study of genomic instability and chemoresistance.
• • BRCA1/BRCA2 knockout lines: In HR-proficient cells, knockout of BRCA1 or BRCA2 creates HR-deficient models for PARP inhibitor sensitivity studies.
• • KRAS G12D/G12V knock-in lines: In low-grade serous models, introduction of mutant KRAS enables study of MAPK pathway activation and targeted therapy resistance.
• • Reporter lines: GFP or luciferase knock-in under endogenous promoters (e.g., CA125/MUC16) for real-time monitoring of tumor growth and metastasis.

Commercially available, sequence-verified CRISPR-edited cell lines accelerate research by eliminating the need for in-house editing and validation, providing reproducible and reliable models for functional genomics and drug discovery.

• • Gene-edited cell lines are essential for validating the functional role of genes identified in genomic studies. For example:
• • TP53 knockout in A2780 cells demonstrated that loss of p53 increases resistance to cisplatin and doxorubicin, confirming its role in chemosensitivity.
• • BRCA1 knockout in OVCAR8 cells showed increased sensitivity to PARP inhibitors (e.g., olaparib) and enhanced genomic instability, as measured by micronuclei formation.
• • ARID1A knockout in Kuramochi cells revealed that loss of ARID1A leads to defective chromatin remodeling and increased sensitivity to EZH2 inhibitors.

• • Isogenic pairs (wild-type vs. knockout/knock-in) are powerful tools for drug screening and resistance modeling:
• • PARP inhibitor screening: BRCA1 wild-type vs. BRCA1 knockout isogenic pairs are used to identify compounds that selectively kill HR-deficient cells.
• • Platinum resistance: TP53 knockout models are used to study mechanisms of acquired resistance to carboplatin and cisplatin, including upregulation of drug efflux pumps (e.g., ABCB1) and enhanced DNA repair.
• • Targeted therapy resistance: KRAS G12D knock-in models are used to screen for MEK and ERK inhibitors and to study adaptive resistance mechanisms (e.g., feedback activation of PI3K).

• • CRISPR-based screens using gene-edited cell lines enable the identification of synthetic lethal interactions and biomarkers:
• • Synthetic lethality screens: In BRCA1-deficient cells, genome-wide CRISPR knockout screens identified genes such as PARP1, POLQ, and RAD52 as essential for survival, leading to new therapeutic targets.
• • Resistance biomarkers: In TP53 knockout models, CRISPR activation screens identified genes whose overexpression confers resistance to platinum drugs, such as ERCC1 and FANCD2.
• • Immune evasion: Knockout of MHC class I components (e.g., B2M) in ovarian cancer cell lines helps identify mechanisms of immune escape and potential targets for checkpoint blockade.